We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Topical Therapy Safely Treats Serious Skin Infections

By HospiMedica staff writers
Posted on 04 Oct 2007
A new topical lotion that penetrates the skin deeply enough to target and eliminate serious skin infections, but without being systemically absorbed, has shown a high degree of safety and tolerability, according to a new phase I study. More...


NB-002 is a topical oil-in-water nanoemulsion combined with an antimicrobial agent. The nanoemulsion undergoes a high-energy process to shrink the particles so they are small enough to enter the skin through pores and hair follicles but too large to penetrate the tight junctions of the epithelium. In a phase I study to test the product, developed by NanoBio Corporation (Ann Arbor, MI, USA) a spin-off from the University of Michigan (Ann Arbor, MI, USA), 20 subjects with advanced onychomycosis (toenail fungus) were randomized to receive two strengths of NB-002. Treatments were applied twice daily for 28 days to both affected and unaffected toenails and a small area of surrounding skin. Results showed that systemic drug absorption was below quantifiable limits for all subjects throughout the study period. Additionally, the trial showed that NB-002 had no safety or dermal irritation concerns. The study was presented at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, held during September 2007, in Chicago (IL, USA).

"At present, the vast majority of people with onychomycosis are untreated as a result of concerns for the serious toxicities associated with the available oral medications,” said lead author James Baker, M.D., chief science officer and founder of NanoBio. "Our safety data, combined with early information from the ongoing phase 2 trial, indicate that NB-002 is potentially the first treatment for onychomycosis that is highly efficacious and very safe.”

Onychomycosis is a chronic persistent fungal infection of the nail bed resulting in thickening and discoloration of the nail accompanied by serious pain and disability. Fungal infections of the nail bed affect 25% of adults and this rate rises with age. Systemic treatments have significant safety risks and a high relapse rate (40%). Available topical treatment, on the other hand, has a low efficacy rate (5-12%).


Related Links:
NanoBio Corporation
University of Michigan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.